Hilak forte drops d / vn. admission bottle - 30ml dropper # 1

Release form, composition and packaging

?

Drops for oral administration in the form of a clear or slightly cloudy solution of yellowish-brown color with a characteristic sourish caramel-like odor.

100 ml

aqueous substrate of metabolic products Escherichia coli DSM 4087 * 24.9481 g

aqueous substrate of metabolic products Enterococcus faecalis DSM 4086 * 12.4741 g

aqueous substrate of metabolic products Lactobacillus acidophilus DSM 4149 * 12.4741 g

aqueous substrate of metabolic products Lactobacillus helveticus DSM 4183 * 49.896 g

* substrates contain lactose.

sodium phosphate heptahydrate - 1.159 g, dipotassium phosphate - 1.265 g, lactic acid - 2.5-6.25 g, concentrated phosphoric acid - 0.352 g, potassium sorbate - 0.1114 g, citric acid monohydrate - 0.0322 g, water - up to 100 ml.

1.1 ml - sachet made of varnished polyethylene terephthalate / aluminum / polyethylene laminated foil (30) - cardboard packs.

2.2 ml - sachet made of varnished polyethylene terephthalate / aluminum / polyethylene laminated foil (30) - cardboard packs.

30 ml - dark glass bottles (1) with a dropper stopper and a plastic cap with first opening control - cardboard packs.

100 ml - dark glass bottles (1) with dropper stopper and plastic cap with first opening control - cardboard packs.

pharmachologic effect

The natural physiological microflora of the intestine can be significantly disturbed by such external influences as antibiotic therapy, radiation, stomach surgery, as well as due to inappropriate and unusual nutrition, changes in water, climate change and other conditions. Hilak forte regulates the balance of intestinal microflora and normalizes its composition. Due to the content of normal microflora metabolic products in the preparation, Hilak forte helps to restore normal intestinal microflora in a biological way and allows preserving the physiological and biological functions of the intestinal mucosa. The biosynthetic lactic acid and its buffer salts, which are part of the preparation, restore the normal value of acidity in the gastrointestinal tract, regardless of whether the patient has increased or decreased acidity.Against the background of the acceleration of the development of normal intestinal symbionts under the action of the drug Hilak forte, the natural synthesis of vitamins of the B and K groups is normalized. electrolyte balance in the intestinal lumen. There is evidence that Hilak forte enhances the protective functions of the body by stimulating the immune response. When using Khilak forte, an acceleration of the elimination of Salmonella in infants after salmonella enteritis is noted, which is due to the stimulation of the growth of acidophilic anaerobic flora and its subsequent antagonistic effect on salmonella. ''

Indications for use

- violations of the physiological flora of the small and large intestine (during and after treatment with antibiotics or sulfonamides, radiation therapy)

- digestive insufficiency syndrome, dyspepsia

- diarrhea, flatulence, constipation

- gastroenteritis, colitis

- senile bowel syndrome (chronic, atrophic gastroenteritis)

- Gastrointestinal disorders caused by climate change

- hypo- and anacid states

- enterogenic diseases of the gallbladder and liver

- allergic skin diseases (urticaria, endogenously caused chronic eczema)

- salmonellosis in the stage of convalescence (including in infants).

Contraindications for use

- hypersensitivity to drug components

- lactase / isomaltase deficiency, lactose intolerance, glucose-galactose malabsorption.

Dosage regimen

Hilak forte

Name ENG

HYLAK FORTE

Clinical and pharmacological group

A drug that regulates the balance of intestinal microflora

ATX code

Antidiarrheal drugs of biological origin, regulating the balance of intestinal microflora

Dosage

etc.

x 30ml

Structure

100 ml contain: Active substances: embryonic aqueous substrate of metabolic products of Escherichia coli DSM 4087 24.9481 g

embryonic aqueous substrate of metabolic products Streptococcus faecalis DSM 4086 12.4741 g

embryonic aqueous substrate of metabolic products Lactobacillus acidophilus DSM 4149 12.4741 g

embryonic aqueous substrate of metabolic products Lactobacillus helveticus DSM 4183 49.896 g. Excipients: sodium phosphate heptahydrate, potassium phosphate, lactic acid, concentrated phosphoric acid, potassium sorbate, citric acid monohydrate

Indications

violations of the physiological flora of the intestine (during and after treatment with antibiotics, sulfonamides, radiation therapy)

digestive insufficiency syndrome, dyspepsia

diarrhea, flatulence, constipation

gastroenteritis, colitis

senile bowel syndrome (chronic, atrophic gastroenteritis)

disorders of the gastrointestinal tract caused by climate change

hypo- and anacid conditions

enterogenic diseases of the gallbladder and liver

allergic skin diseases (urticaria, endogenously caused chronic eczema)

salmonellosis in the stage of convalescence (including in infants).

INN / Active ingredient

An embryonic aqueous substrate of metabolic products Streptococcus faevalis DSM 4086 + an embryonic aqueous substrate of metabolic products Lactobacillus acidophilus DSM 4149 + an embryonic aqueous substrate of metabolic products Esherichia coli DSM 4087 + helical non-embryonic aqueous substrate of metabolic products Lveact318

Contraindications

Hypersensitivity to drug components.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Shelf life: 4 years - vials (6 weeks after opening)

3 years - sachet

Specifications

Scope of the drug

Gastrointestinal tract

Release form

Drops

Manufacturer country

Germany

Package quantity, pcs

one

Scope of application

Gastroenterology

Minimum age from

From birth

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Shelf life after opening

1.5

Volume, ml.

30 ml

Brand name

Hilak forte

The amount of the dosage form in the primary package

30 ml

Primary packaging type

Dark glass bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antidiarrheal agent

Anatomical and therapeutic characteristics

A07FA Antidiarrheal microorganisms

Dosage form

Drops for oral administration

Expiration date in days

1460

The target audience

Children

Package weight, g

thirty

Category

:

Preparations for the gastrointestinal tract

,

Dysbacteriosis

,

Probiotics and prebiotics

,

Inulins

Mode of application

:

For adults, the drug is prescribed 40-60 drops 3 times / day < br> < br> children - 20-40 drops 3 times / day < br> < br> babies - 15-30 drops 3 times / day. < br> < br> After improvement of the condition, the initial daily dose of Hilak forte can be reduced by half. < br> < br> < br> < br> The drug is taken orally before or during a meal, diluted in a small amount of liquid, excluding milk.

Dosage (volume) of the substance in the preparation

:

embryonic aqueous substrate of metabolic products of Escherichia coli DSM 4087 ................ 24.9481 g, embryoless aqueous substrate of metabolic products Streptococcus faecalis DSM 4086 .... 12.4741 g, embryonic aqueous substrate of products metabolism Lactobacillus acidophilus DSM 4149 .. 12.4741 g, embryonic water substrate of metabolic products Lactobacillus helveticus DSM 4183 ... 49.8960 g

Information on technical characteristics, delivery set, country of manufacture